Nearly one in five cancer drugs tested in Ethiopia, Kenya, Malawi, and Cameroon were found to be defective, raising serious health concerns across Africa. A new study published in The Lancet Global Health revealed the disturbing news, stating that 17% of nearly 200 products lacked proper active ingredient levels. The issue stems from a mix of poor manufacturing, improper storage, and counterfeit drugs, with most defects undetectable by simple visual checks. Experts warn that these flawed medicines can lead to treatment failure and economic loss. While these countries have well-equipped labs, most lack the capacity to handle the toxicity of cancer medications and, as a result, do not test them. To address the problem, the researchers recommend improving regulation as well as providing equipment and training where necessary. The WHO is now working with affected countries to boost regulation, testing, and surveillance systems.
DW
